Table 1.
Characteristics of included studies.
| Study | Country | Case (T/C, n) | Age (T/C, y) | Sex (M/F) | Intervention | Baseline CVP (T/C) | Surgery | Diagnosis | |
|---|---|---|---|---|---|---|---|---|---|
| T | C | ||||||||
| Otsubo et al. 2004 [13] | Japan | 47/56 | 59.3 ± 14.4/55.4 ± 16.1 | 30/17 | 41/15 | IVCC/control | 10.6 ± 2.6/10.1 ± 2.8 | Hepatectomy | Hepatocarcinoma (28/31), metastatic tumor (10/14), cholangiocellular carcinoma (5/4), others (4/7) |
|
| |||||||||
| Chen et al. 2006 [14] | China | 60/58 | 39.7 ± 3.6/41.5 ± 4.1 | 53/7 | 51/7 | IVCC/control | 7.6 ± 3.0/7.7 ± 2.4 | Hepatectomy | HBV related cirrhosis (51/54), HCV related cirrhosis (6/4), others (1/2) |
|
| |||||||||
| Wang et al. 2006 [15] | China | 25/25 | 45.3 ± 14.6/46.0 ± 12.1 | 19/6 | 21/4 | IAC/control | — | Hepatectomy | Liver cirrhosis (14/15), others (11/10) |
|
| |||||||||
| Kato et al. 2008 [16] | Japan | 43/42 | 65 (28–82)/67 (38–79)∗ | — | — | IVCC/control | 7 (3–14)/7 (2–16)∗ | Liver resection | Hepatocarcinoma (35/34), metastatic tumor (6/7), cholangiocellular (1/0) |
|
| |||||||||
| Liu et al. 2008 [17] | China | 23/23 | 45.4 ± 13.0/42.9 ± 12.6 | 14/9 | 16/7 | IAC/control | 2.7–5.4 | Liver resection | Hepatocarcinoma (23/23) |
|
| |||||||||
| Uchiyama et al. 2009 [18] | Japan | 20/58 | 61.6 ± 12.9/64.8 ± 16.8 | 15/5 | 44/14 | IVCC/control | — | Hepatectomy | Hepatocarcinoma (9/31), metastatic tumor (6/20), others (5/7) |
|
| |||||||||
| Feng et al. 2010 [19] | China | 43/43 | 48 ± 10/47 ± 12 | 6/37 | 8/35 | IAC/control | 10 (6–12)/10 (6–11)∗ | Transplantation | Hepatocirrhosis (15/16), severe hepatitis (7/8), carcinoma (19/17), others (2/2) |
|
| |||||||||
| Liu et al. 2010 [20] | China | 67/83 | 51 (33–69)/55 (14–76)∗ | 48/35 | 55/12 | IVCC/control | 7.8 ± 3.5/8.3 ± 3.6 | Liver lobectomy | Primary liver carcinoma (67/83) |
|
| |||||||||
| Rahbari et al. 2011 [21] | Germany | 65/63 | 57.2 ± 10.9/59.2 ± 12.1 | 37/28 | 42/21 | IVCC/IAC | 9.2 ± 3.6/7.6 ± 3.6 | Liver resection | Hepatocarcinoma (19/20), metastatic tumor (35/37), others (11/6) |
|
| |||||||||
| Zhu et al. 2012 [22] | China | 96/96 | — | — | — | IVCC/IAC | 10.5 ± 1.3/10.8 ± 1.2 | Liver resection | Liver tumors (96/96) |
|
| |||||||||
| Yang et al. 2013 [23] | China | 60/53 | 48.7 ± 10.8/49.5 ± 12.1 | 43/17 | 38/15 | IVCC/control | 7.6 ± 3.2/— | Hepatectomy | Hepatocarcinoma (31/26), metastatic tumor (7/7), others (22/20) |
|
| |||||||||
| Ryu et al. 2010 [24] | South Korea | 19/19 | 29 ± 11/26 ± 9 | 15/3 | 18/1 | IAC/control | 8.5/7.5 | Liver lobectomy | Donors (19/19) |
|
| |||||||||
| Wang et al. 2013 [25] | China | 33/32 | 37.1 ± 10.1/35.9 ± 10.3 | 26/7 | 26/6 | IAC/control | — | Liver lobectomy | Hepatocarcinoma (11/18), hepatocirrhosis (16/12), hepatitis B (4/1), others (2/1) |
IVCC: infrahepatic inferior vena cava clamping; IAC: low central vein pressure by intraoperative anesthetic control; T: treatment group; C: control group.
∗Data were presented as median (range).